Thermo Fisher Scientific’s PPD Business Awarded Cancer-Support Contract
PPD, the Wilmington-based clinical research business of Thermo Fisher Scientific, has been awarded a 10-year contract by the National Cancer Institute to support cancer clinical trials.
The maximum value of the contract is $548 million, if all options are exercised, according to HigherGov, a company that monitors government grants and contract opportunities for businesses.
As part of the award, PPD will support the collection and migration of electronic patient-reported outcomes and other patient-generated health data into clinical trials supported by the NCI’s Cancer Trials Support Unit.
“NCI’s focus on progressing cancer research across the nation is one we all support, to advance scientific knowledge and to help all people live longer, healthier lives,” said David M. Johnston, Ph.D., senior vice president and president, clinical research at Thermo Fisher Scientific. “The research that NCI champions is vital to improving the outcomes of patients battling this group of diseases. We are privileged to support NCI in those efforts.”
PPD, acquired by Thermo Fisher Scientific last year for $17.4 billion, has three decades of experience helping governmental agencies, contractors and nonprofits conduct therapeutic, vaccine and medical device studies.
The business, which employs more than 30,000 people worldwide, has conducted over 675 oncology and hematology studies in the last five years involving more than 114,000 patients at over 26,000 sites around the world. PPD also helped develop 24 of the top 25 best-selling oncology drugs of 2020.
Cancer is among the leading causes of death worldwide. In 2022, NCI estimates there will be more than 1.9 million new cases of cancer and more than 600,000 cancer deaths in the United States.
Globally, the World Health Organization notes that nearly one in every six deaths can be attributed to cancer, with about 400,000 children developing cancer every year.